BLOG

How to Weigh the Evidence Before Adipose Stem Cell Therapy in Osaka

Published 2026.10.15 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

Search for regenerative medicine online and you will find enthusiastic headlines, cautious scientific reviews, and everything in between. For international patients considering adipose-derived stem cell therapy in Japan, it can be hard to know which sources deserve weight. This article explains how to read the evidence calmly, what is still uncertain, and how to prepare questions for a medical consultation at Grand Green Osaka Umekita Clinic or any other facility you are comparing.

The short answer: promising research, real uncertainty

Mesenchymal stem cells, including those obtained from fat tissue, have been studied worldwide for their reported ability to release anti-inflammatory substances and growth factors that may support tissue repair. Early clinical studies, particularly in joint conditions such as osteoarthritis, have reported encouraging signals in some patients. At the same time, studies differ in cell preparation, dose, route of administration, follow-up length, and the way outcomes are measured. Because of this variation, results from one study cannot simply be applied to every person or every clinic.

In other words, the field is active and interesting, but it does not offer guarantees. A responsible clinic will explain both sides, and a responsible patient will treat any single study, testimonial, or advertisement as one piece of information rather than a verdict.

What this treatment involves, in brief

Adipose-derived stem cell therapy, as described on the clinic’s treatment page, uses mesenchymal stem cells taken from your own fat tissue. A very small amount of fat is collected under local anesthesia on an outpatient basis. The cells are then cultured and expanded at a specialized facility and returned to your body by intravenous infusion. Because the cells come from you, this autologous approach is generally considered to carry a lower risk of rejection than donor cells, although it does not remove every risk.

Understanding the process matters when you read research, because published studies may use different cell sources, such as bone marrow or donor tissue, and different delivery methods, such as direct injection into a joint. Always check whether a study describes the same kind of treatment you are considering.

How to read a study without being misled

You do not need a medical degree to ask good questions about a research paper. A few habits help.

Look at the study design. Randomized controlled trials with a comparison group generally provide stronger information than small case series without one.
Check the number of participants and the follow-up period. Small studies and short follow-up make it difficult to judge benefit or late side effects.
Notice who is being studied. A paper on knee osteoarthritis does not automatically apply to other conditions or to people with different health backgrounds.
Ask how outcomes were measured. Patient-reported pain scores and imaging findings answer different questions.
Compare several sources. Systematic reviews and public guidance from medical societies or government bodies place individual papers in context.

When a public guideline and a single paper seem to disagree, the more cautious, broadly reviewed position is usually the better starting point. PubMed is a useful place to find original papers and reviews, and your doctor can help you interpret what you find.

Understanding the Japanese regulatory context

In Japan, treatments that use cultured human cells are provided under the Act on the Safety of Regenerative Medicine. Facilities submit a regenerative medicine provision plan that is reviewed by a certified committee and submitted to the Ministry of Health, Labour and Welfare, and cell culture is carried out at registered or licensed facilities. This framework is designed to support oversight of quality and patient protection.

It is important to understand what this does and does not mean. Operating under the Act means the clinic follows a defined legal process. It is not the same as a national approval of the treatment for a specific disease. Adipose-derived stem cell therapy is offered as a self-pay (non-insured) treatment, so national health insurance does not cover it, and costs are set by each clinic. Fees, treatment schedule, risks, and possible side effects should be confirmed directly with a physician before you decide.

Questions to bring to your consultation

A consultation is not a commitment. It is a chance to test whether the explanation you receive matches the level of evidence available. International patients may find it helpful to prepare these questions in advance and, if needed, request interpretation support.

Is my condition one for which research on this type of cell therapy exists, and how strong is that research?
What are the possible risks, side effects, and reasons the treatment might not be suitable for me?
How should my current treatments and standard medical care continue alongside this option?
Which facility cultures the cells, and how is the process managed under Japanese law?
What is the full schedule, including time in Osaka, culture period, and follow-up after I return home?
What are the total fees, and what is not included?

Bringing your previous medical records, imaging, and a list of current medications helps the doctor judge whether this option is appropriate. Regenerative therapy is not a replacement for standard medical care, and a physician may recommend other approaches depending on your situation.

Planning your next step

Grand Green Osaka Umekita Clinic is located in Umeda, Osaka, and provides an information page for international patients in English and other languages, so you can review the treatment flow, fees, and frequently asked questions before contacting the clinic. Reading that page alongside independent sources gives you a more balanced picture than any single article can.

To summarize, adipose-derived stem cell therapy is an area of active research with encouraging but incomplete evidence. Weigh study design and relevance, understand what Japan’s regulatory framework does and does not mean, and use your consultation to ask direct questions about suitability, risks, and cost. The decision belongs to you and your physician, made together after an in-person medical assessment.

Before You Decide

Check study designSize and follow-up matter
Know Japan's rulesProcess is not approval
Confirm self-pay termsFees and risks with a doctor
Consult a physicianSuitability needs an exam

This figure is a conceptual summary of the article content

Learn more about Adipose-Derived Stem Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to Adipose-Derived Stem Cell Therapy ›